IDO1 and cancer: Dysregulation in the KYN pathway, particularly the over-expression of the IDO1, TDO2 and KMO enzymes, has been extensively shown to be associated with the progression of various cancers, including breast25,59, colorectal60, glioblastoma61 and liver cancer62.